

CURRICULUM VITAE
of
JAMIE D CAVENAGH

June 2018

PERSONAL DETAILS

<i>Name</i>	Jamie Durrell Cavenagh	
<i>Work address</i>	Consultant (Honorary Professor) in Haematology Department of Haematology St Bartholomew's Hospital London EC1A 7BE	
<i>Date of birth</i>	10th October 1958	
<i>Marital status</i>	Married, two children	
<i>Nationality</i>	British	
<i>Qualifications</i>	BA (Hons)	July 1980
	MB, BS	July 1985
	MRCP (UK)	Mar 1988
	MRCPath	May 1996
	MD (London)	Nov 1996
	FRCP (UK)	Sept 2003
	FRCPPath	Jan 2004
<i>MD title</i>	'Adhesive interactions of leukaemic cells with endothelium'	
<i>Accreditation</i>	JCHMT accreditation in Haematology	May 1996
	Entered on specialist register	June 1996
<i>GMC registration</i>	3066104	
<i>MPS number</i>	175168	
<i>Radiation Protection</i>	Cert no. 296/34 (Feb 1996)	

GENERAL AND UNDERGRADUATE EDUCATION

York University	1977-1980
B.A.(Hons, Class 2.1) English Literature	
St Mary's Hospital Medical School, London	1980-1985

AWARDS AND DISTINCTIONS

Martin J.Turner Scholarship (2nd MB overall)	June	1981
Agnes Cope Prize (Pathology project)	June	1984
University Distinctions in Pathology and Surgery	July	1985
BSH Trust travel award	Jan	1990
LRF Scientific Training Fellowship	Feb	1992
BSH Young Investigator of the Year runner-up	April	1994
BSH Scientific Scholarship	Feb	2000

POSTGRADUATE APPOINTMENTS

<i>September 2011</i>	Consultant (Honorary Professor) in Haematology Barts Health NHS Trust
<i>January 2009-August 2011</i>	Consultant (Honorary Reader) in Haematology Barts Health NHS Trust
<i>September 2003-Dec 2008</i>	Consultant (Honorary Senior Lecturer) in Haematology Barts Health NHS Trust
<i>October 1997-September 2003</i>	Senior Lecturer (Honorary Consultant) in Haematology St Bartholomew's and the Royal London School of Medicine and Dentistry
<i>February 1994-October 1997</i>	Lecturer (Honorary Senior Registrar) in Haematology St Bartholomew's and the Royal London School of Medicine and Dentistry
<i>February 1992-January 1994</i>	Leukaemia Research Fund Scientific Training Fellow Honorary Registrar in Haematology St George's Hospital Medical School
<i>February 1989-January 1992</i>	Registrar in Haematology (SGH rotation) St George's Hospital The Royal Marsden Hospital The Royal Surrey County Hospital, Guildford
<i>August 1988-January 1989</i>	SHO to the Leukaemia Unit The Royal Marsden Hospital
<i>August 1986-July 1988</i>	Rotating Medical SHO St Peter's Hospital, Chertsey
<i>August 1985-July 1986</i>	Pre-registration HO Central Middlesex Hospital, Acton & The Royal Surrey County Hospital, Guildford

FELLOWSHIP / MEMBERSHIP OF LEARNED SOCIETIES

Royal College of Physicians
Royal College of Pathologists
British Society for Haematology
British Medical Association
American Society of Hematology
American Society of Clinical Oncology
European Hematology Association

POSITIONS OF RESPONSIBILITY

- Clinical Lead in Haemato-oncology, Cancer CAU (2008-2012)
- MDT Chair in Haemato-oncology, Cancer CAU (2010-2013)
- Chairman, NE Thames Haematology Tumour Board (2008-10)
- NICE MTA clinical advisor for Thalidomide and Bortezomib upfront (2010)
- NICE STA clinical advisor for Lenalidomide (2008)
- NCRI Haem-Onc CSG (2010-)
- NCRI MM CSG (2007-)
- NCRI MDS CSG (2007-)
- NCRI AML CSG (2007-)
- NCRI Local Studies Approval Committee (2005-2008)
- NICE STA clinical advisor for Bortezomib and Lenalidomide (2006-2009)
- NICE Patient access Schemes Liaison Unit consultee (2010-)
- Leukaemia & Lymphoma Research Clinical Trials Committee (2011-)
- Anthony Nolan Medical Advisory Board (2011-)
- Critical Care Board for SBH (2005-2010)
- Cancer Services D&T committee (2003-)
- British Society for Blood and Marrow Transplantation clinical trials committee (2002-)
- European Blood and Marrow Transplant Group Chronic Leukaemia & Myeloma Working Group Member (2003-)
- North East Thames Haematology SpR Programme Director & BLT Unit Training Director (1998-2004)
- UK Myeloma Forum Elected Executive Committee Member (1999-2012)
- UK Myeloma Forum Elected Chairman (2008-2012)
- UK Myeloma Forum Elected Clinical Trials Committee Chairman (2003-8)
- International Myeloma Forum (UK) Scientific Board (2004-)
- North East Thames Cancer Network Haemato-oncology Research Coordinator (2002-2011)
- North Thames Haematology Specialist Training Committee, Vice Chairman & RITA panel member (1998-2004)
- Consultant responsible for immunophenotyping (1997-2004)
- Consultant responsible for transfusion & Hospital Transfusion Committee member (1997-2000)

- Referee for journals (Blood, JCO, BJH, BMT, PMJ, JRSM, Hematology, BJC, Haematologica, Leukemia Research)

RESEARCH ACTIVITIES AND GRANT INCOME

- Myeloma UK Early Phase Clinical Trial Centre, £232,770 award for three years (2011-)
- Leukaemia & Lymphoma Research Therapy Acceleration Programme (TAP) Centre, £92,000 award for two years (2011-)
- 'Serial analysis of markers of angiogenesis and apoptosis in patients with multiple myeloma'
Clinical Research Fellow funded by the Special Trustees of St Bartholomew's Hospital (Dr Heather Oakervee, MD Thesis) (2001-2003)
- 'Exploring synergy between proteasome inhibition and genotoxic agents in multiple myeloma: in vitro and clinical studies'
Clinical Research Fellow funded by the Special Trustees of St Bartholomew's Hospital (Dr Rakesh Popat, PhD Thesis) (2004-2008)

UK CHIEF INVESTIGATOR FOR CURRENT MULTICENTRE CLINICAL TRIALS

- Phase I/II Myeloma UK trial of VTD-Panobinostat in relapsed MM (MUK-6)
- Phase I/II study of MLN9708 in combination with MP in older, untreated MM patients (C16006)
- Phase I/II randomised study of panobinostat with azacytidine in high risk MDS (CLBH589H2101)
- Phase I/II trial of Daratumumab in combination with Lenalidomide and Dexamethasone in relapsed MM (GEN503)
- Phase II Randomised trial of Siltuximab in smouldering MM (CNT0328SMM2001)
- Phase I/II study of KW-2478 in combination with bortezomib in MM (2478-INT-001)
- Phase III of panobinostat in combination with bortezomib in MM (PANORAMA)
- Phase III MM020 (FIRST)
- Phase III study of azacytidine in older patients with AML (AZA-AML-001)
- Phase II randomised study of CNT0328 and bortezomib in MM (CO328T06)
- Phase II trial of sequential chemotherapy and reduced intensity allogeneic transplant in refractory/relapsed AML (single centre, undergoing analysis)
- Mutational screening in familial AML (single centre)

PRINCIPLE INVESTIGATOR IN CURRENT MULTICENTRE CLINICAL TRIALS

- NCRI AML-17 (largest UK recruiting centre)
- Phase II randomised trial of Azacytidine with Vorinostat in MDS/AML (RAVVA)
- Phase 3 study comparing Revlimid / Dexamethasone with Revlimid /Dexamethasone plus Daratumumab in relapsed/refractory myeloma (POLLUX)

- Phase II study of CCD vs CVD in myeloma patients at first relapse (MUK-5)
- Phase I trial of azacytidine and lenalidomide in relapsed AML post transplant (VIOLA)
- CCD with maintenance carfilzomib in transplant-eligible myeloma patients (CARDAMON)
- Phase III study of Pomalidomide versus Dexamethasone in relapsed MM (NIMBUS)
- Phase III study of oral azacytidine in low-risk MDS (QUAZAR)
- Phase I study of KHK2823 in patients with acute myeloid leukaemia or myelodysplastic syndrome (EudraCT No 2013-003657-21)
- NCRI AML-16 (recruited)
- Phase II study of PAD: impact of MRD in patients with deferred ASCT (PADIMAC)
- Phase II study of adjunctive lenalidomide in MM patients undergoing RIC Allo SCT (LenaRIC)
- Phase II randomised study of different bendamustine doses with thalidomide and dexamethasone in MM (MUK-1)
- Phase II study of sodium valproate/azacytidine in AML (VAL/AZA)
- Phase II study of lenalidomide with chemotherapy in AML/MDS with chromosome 5 abnormalities (AML Len5)
- Phase II study of azacytidine in CMML (CMML201)
- Phase III study of lenalidomide in non-5q- MDS (MDS005)
- NCRI MM X
- NCRI MM XI
- NCRI SPIRIT-2 in CML

SELECTION OF COMPLETED TRIALS

- PAD therapy for untreated MM patients
- IV Melphalan/bortezomib for treated MM patients (VEL-03-80)
- NCRI AML-15 (4th largest UK recruiting centre)
- CHIR258 in AML/MM (TKI258)
- SRT501 alone or with bortezomib in MM (SRT501012)
- Low-dose ATG in elderly AA
- EBMT SAA trial of ATG/CyA +/- G-CSF
- ATG in low risk MDS
- NCRI MM IX

UKMF ACTIVITIES

- Elected Chairman (2008-2012)
- Prior elected Clinical Trials Group Chairman
- Organisation of Scientific and Education Days
- Speaker at annual Scientific and Educational Days
- Guideline development for MM & AL Amyloidosis
- Speaker at national and local myeloma patient support groups

TEACHING EXPERIENCE

Extensive teaching experience at undergraduate and postgraduate levels, in particular:

- Prior Unit Training Director and NE Thames Haematology SpR Programme Director
- North Thames SpR Teaching Programme
- London Joint Oncology Course
- BLT MRCP course, MRCS & FDS courses
- UKMF Educational and Scientific Days

PRESENTATIONS AT NATIONAL AND INTERNATIONAL MEETINGS

- ASH IMF symposia (2004, 2005)
- EHA MM symposium (2004)
- BSH symposium (2004, 2009)
- BMJ Masterclass (2012, 2013)
- UKG(i)M Update (2013)
- Essex Specialist Nurses Meetings
- Myeloma UK Patient Seminars and National InfoDays (2003-)
- 2nd National Conference on Haematological Malignancies (2010)
- Monitoring and management of iron overload Regional conference (2010)
- European Workop on Epigenetic Therapies (2013)

PUBLICATIONS

Peer reviewed papers and scientific correspondence

Al Seraihi AF, Rio-Machin A, Tawana K, Bödör C, Wang J, Nagano A, Heward JA, Iqbal S, Best S, Lea N, McLornan D, Kozyra EJ, Wlodarski MW, Niemeyer CM, Scott H, Hahn C, Ellison A, Tummala H, Cardoso SR, Vulliamy T, Dokal I, Butler T, Smith M, Cavenagh J, Fitzgibbon J (2018)
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
Leukemia (in press)

Cavenagh JD, Popat R (2018)
Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Clinics in Lymphoma, Myeloma and Leukemia (in press)

Freeman SD, Hills RK, Virgo P, Khan N, Couzens S, Dillon R, Gilkes A, Upton L, Nielsen OJ, Cavenagh JD, Jones G, Khwaja A, Cahalin P, Thomas I, Grimwade D, Burnett AK, Russell NH (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Journal of Clinical Oncology. 36. 1486-1497.

Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh JD, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H (2018)
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
BMC Cancer. 14. 852.

Davies J, Hassan S, Sarker S, Besley C, Oakervee H, Smith M, Tausig, Gribben J & Cavenagh J (2018)
Durable graft-versus-leukaemia effects without donor lymphocyte infusions – results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia (2018)
British Journal of Haematology. 180. 346-355.

Facon T, Dimopoulos M, Dispenzieri A, Catalano J, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Gherdes C, Lee J, Chen C, Oriol A, De La rubia J, White D, Binder D, Lu j, Anderson K, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L & Hulin C (2018)
Final analysis of survival outcomes in the randomised phase 3 FIRST trial.
Blood. 131. 301-310.

Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo, Rabin N, Kurman M, Novak B, Shiraishi N, Nakashima D, Akinaga S & Yong K (2017)
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
British Journal of Cancer. 117. 1295-1302.

Tawana K, Wang J, Kiraly PA, Benyo G, Zombori M, Csomor J, Al Seraihi A, Rio-Machin A, Matolcsy A, Chelala C, Cavenagh J, Fitzgibbon J & Bodor C (2017)
Recurrent somatic JAK-STAT pathway variants within a RUNX-1-mutated pedigree.
European Journal of Human Genetics. 25. 1020-1024.

Garcia-Manero G, Sekeres M, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, De Angelo D, Stauder R, Yee K, Zhu N, Lee J, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M & Ottmann O (2017)
A Phase 1b/2b multicentre study of oral panobinostat plus azacytidine in adults with MDS, CMML or AML with < 30% blasts.
Leukemia. 31. 2799-2806.

Craddock C, Houlton A, Quek L, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin M, Pillai S, Kelly R, Siddique S, Dennis M, Cavenagh J & Vyas P (2017)
Outcome of Azacytidine therapy in acute myeloid leukemia is not improved by concurrent Vorinostat therapy but is predicted by a diagnostic molecular signature.
Clinical Cancer Research. 23. 6430-6440.

Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, Konig H, Levis MJ, Burnett AK (2017)
A randomised assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT-3 mutated AML.
Blood. 129. 1143-1154.

Killick S, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden J, Samarasinghe S, Wood A & Marsh J (2017)
BCSH Guidelines for Aplastic Anaemia: Single centre retrospective review finds no compelling evidence for the recommended higher platelet count threshold of $20 \times 10^9/l$ – Response to Yan *et al*
British Journal of Haematology (in press)

Zaidi A, Lai M & Cavenagh J (2017)
Long-term stabilisation of myeloma with curcumin.
BMJ Case Reports, April

Subramanian J, Cavenagh J, Desai B & Jacobs I (2017)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.

Cancer Management Research. 9. 131-140.

Popat R, Brown SR, Flanagan L, Hall A, Gregory W, Kishore B, Streetly M, Oakervee H, Yong K, Cook G, Low E & Cavenagh J; Myeloma UK Early Phase Clinical Trial Network (2016)

Bortezomib, thalidomide, dexamethasone and panobinostat for patients with relapsed multiple myeloma (MUK-six: a multicentre, open-label, phase I/II trial. *Lancet Haematology*. 3. e572-580.

S.Killick, N.Brown, J.D.Cavenagh, I.Dokal, T.Foukaneli, A.Hill, P.Hillmen, R.Ireland, A.Kulasekararaj, G.Mufti, J.Snowden, S.Samarrasinghe, A.Wood & J.Marsh (2016)

Guidelines for the diagnosis and management of aplastic anaemia.

British Journal of Haematology. 172. 187-207.

A.Burnett, J.D.Cavenagh, N.Russell, R.Hills, J.Kell, G.Jones, O.Nielsen, A.Khwaja, I.Thomas & R.Clark (2016)

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m² with 6 mg/m² in the NCRI AML17 trial.

Haematologica. 101. 724-731.

G.Cook, A.Ashcroft, D.Cairns, C.Williams, J.Brown, J.D.Cavenagh, J.Snowden, C.Parrish, K.Yong, J.Cavet, H.Hunter, J.Bird, H.Pratt, S.Chown, E.Heartin, S. O'Connor, M.Drayson, A.Hockaday and T.Morris (2016)

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse (Intensive): a randomised, open-label, phase 3 trial.

Lancet Haematology. 3. e340-351.

K.Yong, J.Cavet, P.Johnson, C.Williams, D.Nakashima, S.Akinaga, H.Oakervee & J.D.Cavenagh (2016)

Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.

British Journal of Cancer. 114. 7-13.

S. Brown, S.Hinsley, M.Ballesteros, S.Bourne, P.McGarry, D.Sherratt, L.Flanagan, W.Gregory, J.D.Cavenagh, R.Owen, C.Williams, M.Kaiser, E.Low & K.Yong for the Myeloma UK Clinical Trials Network (2016)

The MUK five protocol: a Phase II randomised, controlled, parallel group, multi-centre trial of carilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, bortezomib (Velcade) and dexamethasone for first relapse and primary refractory multiple myeloma.

BMC Hematology. 16. 14.

C.Parrish, C.Morris, C.Williams, D.Cairns, J.D.Cavenagh, J.Snowden, J.Ashcroft, J.Cavet, H.Hunter, J.Bird, A.Chalmers, J.Brown, K.Yong, S.Schey, S.Chown & G.Cook (2016)

Stem cell harvesting after bortezomib-based reinduction for myeloma relapsing after autologous transplantation: Results from the British Society of Blood and Marrow Transplantation / United Kingdom Myeloma Forum X (Intensive) Trial.

Biology of Blood and Marrow Transplantation. 22. 1009-1016.

S.Usmani, J.D.Cavenagh, A.Belch, C.Hulin, S.Basu, D.White, A.Nooka, A.Ervin-Haynes, W.Yiu, Y.Nagarwala, A.Berger, C.Pelligra, S.Guo, G.Binder, C.Gibson & T.Facon (2016)

Cost effectiveness of lenalidomide and dexamethasone versus Bortezomib and melphalan and prednisolone in transplant-ineligible US patients with newly diagnosed multiple myeloma.

Journal of Medical Economics. 19. 243-258.

K.Tawana, J.Wang, A. Renneville, C. Bödör, R.Hills, C.Loveday, A.Savic, F. van Delft, J.Treleaven, P.Georgiades, E.Ugnow, N.Asou, N.Uike, M.Debeljak, J.Jazbec, P.Ancliff, R.Gale, X.Thomas, V.Mialou, K.Döhner, L.Bullinger, B.Mueller, T.Pabst, M.Stelljes, B.Schlegelberger, E.Wozniak, S.Iqbal, J.Okosun, S.Araf, A-K.Frank, F.Lauridsen, B.Porse, C.Nerlov, C.Owen, I.Dokal, J.Gribben, M.Smith, C.Preudhomme, C.Chelala, J.D.Cavenagh, J.Fitzgibbon (2015)

Disease Evolution and Outcomes in Familial Acute Myeloid Leukemia with Germline CEBPA Mutations.

Blood. 126. 1214-1223.

F. Miraki-Moud, E.Ghazaly, L.Ariza-McNaughton, K.Hodby, A.Clear, F.Anjos-Afonso, K.Liapis, M.Grantham, F.Sohrabi, J.Cavenagh, J. Bomalaski, J.Gribben, P. Szlosaerek, D.Bonnet & D.Taussig (2015)

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukaemia cells in vivo.

Blood. 125. 4060-4068.

A.Burnett, N.Russell, R.Hills, J.Kell, J.Cavenagh, L.Kjeldsen, M.McMullin, P.Cahalin, M.Dennis, L.Friis, I.Thomas, D.Milligan & R.Clark (2015)

A randomised comparison of daunorubicin 90 mg/m² vs 60 mg/m² in AML induction: results from the UK NCRI AML-17 trial in 1206 patients

Blood. 125. 3878-3885.

H. Dombret, J. Seymour, A. Butrym, A. Wierzbowska, D.Selleslag, J.Ho Jang, R.Kumar, J.Cavenagh, A. Schuh, A. Candoni, C.Récher, I.Sandhu, T. Bernal del Castillo, H.Al-Ali, G.Martinelli, J.Falantes, R. Noppeney, R. Stone, M.Minden, H.McIntyre, S. Songer, L. Lucy, C.L. Beach & H. Döhner (2015)

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Blood. 126. 291-299.

R.Orlowski, L.Gercheva, C.Williams, H.Sutherland, T.Robak, T.Masszi, V.Goranova-Marinova, M.Dimopoulos, J.D.Cavenagh, I.Spicka, A.Surorov, J.Blade, O.Samoylova, T.Puchalski, M.Reddy, R.Bandekar, H. van der Velde, H.Xie & J.Rossi (2015)

A Phase II, randomiized, double-blind, placebo-controlled study of Siltuximab (Anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

American Journal of Hematology. 90. 42-49.

S.Schey, S.Brown, A.Tillotson, K.Yong, C.Williams, F.Davies, G.Morgan, J.Cavenagh, G.Cook, M.Cook, G.Orti, C.Morris, D.Sherratt, L.Flanagan, W.Gregory & J.Cavet (2015)

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomised dose selection trial.

British journal of Haematology. 170. 336-348.

J.Gillmore, A.Wechalekar, J.Bird, J.Cavenagh, S.Hawkins, M.Kazmi, H.Lachmann, P.Hawkins & G.Pratt (2015)

Guidelines on the diagnosis and investigation of AL Amyloidosis.

British Journal of Haematology. 168. 207-218.

A.Wechalekar, J.Gillmore, J.Bird, J.Cavenagh, S.Hawkins, M.Kazmi, H.Lachmann, P.Hawkins & G.Pratt (2015)

Guidelines on the management of AL Amyloidosis.

British Journal of Haematology. 168. 186-206.

L.Benboubker, M.Dimopoulos, A.Dispenxiri, J.Catalano, A.Belch, M.Cavo, A.Pinto, K.Weisel, H.Ludwig, N.Bahlis, A.Banos, M.Tiab, M.Delforge, J.D.Cavenagh, C.Geraldes, J.Lee, C.Chen, A.Oriol, J. de la Rubia, L.Qiu, D.White, D.Binder, J.Anderson, J.Fernand, P.Moreau, M.Attal, R.Knight, G.Chen, J.Van Oostendorp, C.Jacques, A.Ervin-Haynes, H.Avet-Loiseau, C.Hulin & T.Facon (2014)

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

New England Journal of Medicine. 371. 906-917.

J.San-Miguel, V.Hungria, S.Yoon, M.Beksac, M.Dimopoulos, A.Elghandour, W.Jedrzejczak, A.Gunther, T.Nakorn, N.Siritanaratkul, P.Corradini, S.Chuncharunee, J.Lee, R.Schlossman, T.Shelekhova, K.Yong, D.Tan, T.Numbenjapon, J.D.Cavenagh, J.Hou, R.LeBlanc, H.Nahi, L.Qiu, H.Salwender, S.Pulini, P.Moreau, K.Warzocha, D.White, J.Blade, W.Chen, J.de la Rubia, P.Gimsing, S.Lonial, J.Kaufman, E.Ocio, L.Veskovski, S.Sohn, M.Wang, J.Lee, H.Einsele, M.Sopala, C.Corrado, B.Bengoudifa, F.Binlich & P.Richardson (2014)

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Lancet Oncology. 15. 1195-1206.

G.Cook, C.Williams, J.Brown, D.Cairns, J.Cavenagh, J.Snowden, A.Ashcroft, M.Fletcher, C.Parrish, K.Yong, J.Cavet, H.Hunter, J.Bird, A.Chalmers, S.O'Connor, M.Drayson & T.Morris (2014)

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive Trial]): a randomised, open-label, Phase 3 trial.
Lancet Oncology. 15. 874-885.

F.Dignan, S.Aguilar, J.Scarisbrick, B.Shaw, M.Potter, J.D.Cavenagh, J.Apperley, A.Fielding, A.Pagliuca, K.Raj, D.Marks, A. Peniket, C.Crawley, M.Koh & F.Child (2014)

Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.

Bone Marrow Transplantation. 49. 704-708.

G.Pratt, M.Jenner, R.Owen, J.Snowden, J.Ashcroft, K.Yong, S.Feyler, G.Morgan, J.Cavenagh, G.Cook, E.Low, S.Stern, J.Behrens, F.Davies & J.Bird (2014)

Updates to the guidelines for the diagnosis and management of multiple myeloma.

British Journal of Haematology. 167. 131-133.

A.Rohatiner, M.Smith, O.Spinelli, A.Rambaldi, R.Bassan, E.di Bona, F.Rodeghiero, R.Raimondi, M.Bjorkholm, S.Johnson, A.Newland, J.D.Cavenagh, F.Macdougall, R.Waters, J.Fitzgibbon, T.Barbui & A.Lister(2014)

Myeloablative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia – very long follow-up.

British Journal of Haematology. 167. 724-726.

E.Renaudon-Smith, M.Kaur, A.Haroon, J.Cavenagh & T.Butler (2014)

Intravascular haemolysis secondary to *Clostridium perfringens* in a patient with acute myeloid leukaemia undergoing allogeneic stem cell transplantation.

British Journal of Haematology. 165. 743.

D.Smith, J.Stevens, J.Quinn, J.D.Cavenagh, W.Ingram & K.Yong (2014)

Myeloma presenting during pregnancy.

Haematology Oncology. 32. 52-55.

F.Miraki-Moud, F.Anjos-Afonso, K.hodby, E.Griessinger, G.Rosignoli, D.Lillington, L.Jia, J.Davies, J.D.Cavenagh, M.Smith, H.Oakervee, S.Agrawal, J.Gribben, D.Bonnet & D.Taussig (2013)

Acute myeloid leukemia does not deplete normal hemopoietic stem cells but induces cytopenias by impeding their differentiation.

Proc Natl Acad Sci USA. 110, 13576-81.

C.Craddock, L.Quek, N.Goardon, S.Freeman, S.Siddique, M.Raghavan, A.Aztberger, A.Schuh, D.Grimwade, A.Ivey, R.Hills, T.McSkeane, J.Arrazi, S.Knapper, C.Brookes, B.Davies, A.Price, K.Wall, M.Griffiths, J.Cavenagh, R.Majeti, I.Weissman, A.Burnett & P.Vyas (2013)

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
Leukemia. 27. 1028-1036.

J.K.Davies, D.Taussig, H.Oakervee, M.Smith, S.Agrawal, J.D.Cavenagh & J.Gribben (2013)
Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.
British Journal of Haematology. 162. 525-529.

L.Maharaj, C.Marson, Middleton, A.Rioja, J.Perry, H.Oakervee, J.D.Cavenagh, S.Joel & R.Popat (2013)
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
British Journal of Haematology. 163. 135-139.

R.Popat, T.Plesner, F.Davies, G.Cook, M.Cook, P.Elliott, E.Jacobsen, T.Gumbleton, H.Oakervee & J.Cavenagh (2013)
A Phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
British Journal of Haematology. 160. 714-717.

R.Popat, L.Maharaj, H.Oakervee, J.D.Cavenagh & S.Joel (2013)
Schedule dependent cytotoxicity of bortezomib and melphalan in multiple myeloma.
British Journal of Haematology. 160. 111-114.

M.Dennis, D.Culligan, D.Karamitros, P.Vyas, N.Russell, J.Cavenagh, A.Szubert, S.Hartley, J.Brown & D.Bowen (2013)
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
Leukemia Research Reports. 2. 70-74.

H.Longhurst, P.Yong, A.Manson, J.D.Cavenagh, A.Grigoriadou & M.Buckland (2013)
Mullins' syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra.
Quarterly Journal of Medicine. 108. 497-501.

G.Pratt, S. Bowcock, M.Lai, S.Bell, J.Bird, S. D'Sa, J. Cavenagh, G.Cook, G.Morgan, R.Owen, J.Snowden, K.Yong & F.Davies (2013)
United Kingdom Myeloma forum (UKMF) position statement on the use of bendamustine in myeloma.
International Journal of Laboratory Hematology (in press).

A.Islam, S.Rafiq, M.Kirwan, A.Walne, J.Cavenagh, T.Vulliamy & I.Dokal (2013)

Haematological recovery in dyskeratosis congenita patients treated with danazol.

British Journal of Haematology. 162. 854-856.

T.C.Morris, C.Williams, S.Bell, M.Fletcher, A.Szubert, J.Cavenagh, J.Snowden, J.Ashcroft, K.Yong, J.Cavet & G.Cook (2013)

Patient perceptions of second transplants in myeloma: impact on recruitment in the BSBMT/UKMF Myeloma X Relapse (Intensive) Trial.

British Journal of Haematology. 163, 541-543.

C.Bodor, A.Renneville, M.Smith, A.Charazac, S.Iqbal, P.Etancelin, J.Cavenagh, M.Barnett, K.Kramarzova, B.Krishnan, A.Matolcsy, C.Preudhomme, J.Fitzgibbon & C.Owen (2012)

Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Haematologica. 97. 890-894.

J.Vargaftig, D.Taussig, E.Griessinger, F.Anjos-Afonso, T.Lister, J.Cavenagh, H.Oakervee, J.Gribben & D.Bonnet (2012)

Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

Leukemia. 26. 858-860.

R.Auer, F. Macdougall, H.Oakervee, D.Taussig, J.Davies, D.Syndercombe-Court, S.Agrawal, J.D.Cavenagh, T. Lister & J. Gribben (2012)

T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies.

British Journal of Haematology. 157. 580-585.

A.Burnett, N.Russell, D.Culligan, J.Cavenagh, J.Kell, K.Wheatley, A.Virchis, R.Hills & D.Milligan (on behalf of the AML Working Group of the UK National Cancer Research Institute) (2012)

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

British Journal of Haematology. 158. 519-522.

T.Ishii, T.Seike, T.Nakashima, S.Juliger, L.Maharaj, S.Soga, S.Akinaga, J.D.Cavenagh, S.Joel & Y. Shiotsu (2012)

Anti-tumour activity against multiple myeloma by combination of KW-2478, an hsp90 inhibitor, with bortezomib.

Blood Cancer. 2. e68 (Epub 2012 Apr 27)

D.Lichter, H. Danaee, M.Pickard, O.Tayber, M.Sintchak, H.Shi, P.Richardson, J.D.Cavenagh, J.Blade, T.Facon, R.Niesvizky, M.Alsina, W.Dalton, P.Sonneveld, S.Lonial, H. van de Velde, D.Ricci, D.Esseltine, W.Trepicchio, G.Mulligan & K.Anderson (2012)

Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

Blood. 120. 4513-6.

F.Dignan, D.Greenblatt, M.Cox, J.Cavenagh, H.Oakervee, J. J. Apperley, A.Fielding, A.Pagliuca, G.Mufti, K.Raj, D.Marks, P.Amrolia, A.Peniket, P.Medd, M.Potter, B.Shaw & J.Scarisbrick (2012)

Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD.

Bone Marrow Transplantation. 47. 824-830.

N.Joshi, S.Hassan, P.Jasani, S.Dixon, J.Cavenagh, H.Oakervee, M.Smith, S.Agrawal, R.Auer, J. De Vos, L.Langmead, D.Rampton, J.Gribben & D.Taussig (2012)

Bile salt malabsorption in patients with graft-versus-host disease of the gastrointestinal tract.

British Journal of Haematology. 157. 403-407.

M.Mansour Ceesay, E.Matutes, G.Taylor, P.Fields, J.Cavenagh, S.Simpson, A.Ho, S.Devereux, G.Mufti & A.Pagliuca (2012)

Phase II study on combination therapy with CHOP-Zenapax for HTLV-1 associated adult T-cell leukaemia/lymphoma (ATLL).

Leukemia Research. 36. 857-861.

H.Ludwig, H.Avet-Loiseau, J.Blade, M.Boccadoro, J.Cavenagh, M.Cavo, F.Davies, J. de la Rubia, S. Delimpasi, M.Dimopoulos, J.Drach, H.Einsele, T.Facon, H.Goldschmidt, U.Hess, U.Mellqvist, P.Moreau, J.San Miguel, P.Sondergeld, P.Sonneveld, M.Udvardy & A.Palumbo (2012)

European perspective on multiple myeloma treatment strategies: update following recent congresses.

The Oncologist. 17. 592-606.

N.Goardon, E.Marchi, A.Atzberger, L.Quek, A.Schuh, S.Soneji, P.Woll, K.Alford, R.Rout, S.Chauhury, A.Gilkes, S.Knapper, K.Beldford, S.Begum, S.Rose, N.Geddes, M.Griffiths, G.Standen, A.Sternberg, J.D.Cavenagh, H.Hunter, D.Bowen, S.Killick, L.Robinson, A.Price, E.Macintyre, P.Virgo, A.Burnett, C.Craddock, T.Enver, S.Jacobsen, C.Porcher & P.Vyas (2011)

Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

Cancer Cell. 19. 9-10.

M.Scully, V.McDonald, J.Cavenagh, B.Hunt, I.Longair, H.Cohen & S.Machin (2011)

A Phase II study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.

Blood. 118. 1746-53.

T.Farren, J.Giustiniani, F.Liu, D.Tsitsikas, M.Macey, J.Cavenagh, H.Oakervee, D.Taussig, A.Newland, M.Calaminici, A. Bensussan, M.Jenner, J.Gribben & S.Agrawal (2011)

Differential and tumor-specific expression of CD160 in B-cell malignancies.

Blood. 118. 2174-83.

J.Bird, R.Owen, S.D'sa, J.Snowden, G.Pratt, J.Ashcroft, K.Yong, G.Cook, S.Feyler, G.Cook, F.Davies, G.Morgan, J.Cavenagh, E.Low & J.Behrens (2011)

Guidelines for the diagnosis and management of multiple myeloma 2011.
British Journal of Haematology. 154. 32-75.

T.Morris, G.Cook, M.streetley, P.Kettle, M.Quinn, J.Cavet, J.tighe, M.Kazmi, J.Ashcroft, M.Cook, J.Snowden, A.Olujohungbe, S.Marshall, H.Oakervee, R.Popat & J.D.Cavenagh (2011)

Re-transplantation after bortezomib-based therapy.
British Journal of Haematology. 153. 666-668.

H.Ludwig, M.Beksac, J.Blade, J.Cavenagh, M.Cavo, M.Delforge, M.Dimopoulos, J.Drach, H.Einsele, T.Facon, H.Goldschmidt, J-L.Harousseau, U.Hess, M.Kropff, F.Leal da Costa, V.Louw, H.Magen-Nativ, L.Mendeleeva, H.Navi, T.Plesner, J. San Miguel, P.Sonneveld, M.Udvardy, P.Sondergeld & A.Palumbo (2011)

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
The Oncologist. 16. 388-403.

O.Goodyear, A.Agathangelou, I.Novitzky-Basso, S.siddique, T.McSkeane, G.Ryan, P.Vyas, J.Cavenagh, T.Stankovic, P.Moss & C.Craddock (2010)

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Blood. 116. 1908-1918.

D.Taussig, J.Vargaftig, F.Miraki-Moud, E.Griessinger, K.Sharroock, T.Luke, D.Lillington, H.Oakervee, J.D.Cavenagh, S.Agrawal, T.Lister, J.Gribben & D.Bonnet (2010)

Leukemia initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34- fraction.
Blood. 115. 1976-84.

H.Ludwig, M.Beksac, J.Blade, M.Boccardo, J.Cavenagh, M.Cavo, M.Dimopoulos, J.Drach, H.Einsele, T.Facon, H.Goldschmidt, J-L.Harousseau, U.Hess, N.Ketterer, M.Kropff, L.Mendeleeva, G.Morgan, A.Palumbo, T.Plesner, J. San Miguel, O.Shpilberg, P.Sonneveld & S.Zweegman (2010)

Current multiple myeloma treatment strategies with novel agents: a European perspective.
The Oncologist. 15. 6-25.

S.Moore, N.Rabin, J.Cavenagh, D.Playford & K.Yong (2010)

An unusual case of myocardial infarction.
BMJ Case Reports (e-pub 2010 Apr 5).

R.Popat, H.Oakervee, C.Williams, M.Cook, C.Craddock, S.Basu, C.Singer, S.Harding, N.Foot, S.Hallam, L.Odeh, S.Joel & J.D.Cavenagh (2009)

Bortezomib, low-dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma.

British Journal of Haematology. 144. 887-894.

S.Lonial & J.D.Cavenagh (2009)

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.

British Journal of Haematology . 145. 681-708.

J.Marsh, S.Ball, J.D.Cavenagh, P.Darbyshire, I.Dokal, E. Gordon-Smith, J.Keidan, A.Laurie, A.Martin, J.Mercieca, S.Killick, R.Stewart & J.Yin (2009)

Guidelines for the diagnosis and management of aplastic anaemia.

British Journal of Haematology 147. 43-70.

A. Oke, D.Pearce, R.Wilkinson, C.Crafter, R.Odedra, J.D.Cavenagh, J.Fitzgibbon, T.Lister, S.Joel & D.Bonnet (2009)

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukaemia cells in vitro and in vivo.

Cancer Research. 69. 4150-4158.

P. Richardson, P.Sonneveld, M. Schuster. E.Stadtmauer, T.Facon, JL. Harousseau, D.Ben-Yehuda, S.Lonial, H.Goldscmitt, D.Reece, J.Blade, M.Boccardo, J.D.Cavenagh, A.Boral, DL. Esseltine, P.Wey, A.Amato, K.Anderson & J. San Miguel (2009)

Reversibility of symptomatic peripheral neuropathy with bortezomib in the Phase III APEX trial in relapsed multiple myeloma: impact of a dose modification guideline.

British Journal of Haematology. 144. 895-903.

R.Milladi, A.Peniket, T.Littlewood, K.Towlson, R.Pearce, J.Yin, J.D.Cavenagh, C.Craddock, K.Orchard, E.Olavarria, M.Collin & D.Marks (2009)

Alemtuzumab markedly reduces chronic GVHD without affecting survival in reduced-intensity conditioning sibling allo-SCT for adults with AML.

Bone Marrow Transplantation. 43.709-715.

J.Stevens, F.MacDougall, M.Jenner, H.Oakervee, J.D.Cavenagh & T.A.Lister (2009)

Patterns of recruitment into AML-15 and outcome for young patients with AML at a single referral centre.

British Journal of Haematology. 145. 40-44.

F.Davies, C.Morris, J.Bird, G.Cook, C.Williams, J.Tighe, J.Cavenagh, J.Behrens, S.Schey & G.Morgan (for the UKMF) (2009)

United Kingdom Myeloma Forum position statement on the use of lenalidomide in multiple myeloma.

International Journal of Laboratory Hematology. 31.119-131.

D.Tsitsikas, H.Oakervee, J.D.Cavenagh, J.Gribben, S.Agrawal & F.Mattes (2009)

Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanised monoclonal antibody palivizumab: a single centre experience.

British Journal of Haematology. 146. 574-576.

R.Popat, H.Oakervee, S.Hallam, N.Curry, L. Odeh, N.Foot, DL. Esseltine, M. Drake, C. Morris & J.D.Cavenagh (2008)

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up.

British Journal of Haematology. 141. 512-516.

M. Raghavan, L.Smith, D.Lillington, T.Chaplin, I.Kakkas, G.Molloy, C.Chelala, J. Cazier, J.D.Cavenagh, J.Fitzgibbon, T.Lister & B.Young (2008)

Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukaemia.

Blood. 112. 814-821.

D.Taussig, F. Miraki-Moud, F. Anjos-Afonso, D. Pearce, K. Allen, C. Ridler, D. Lillington, H. Oakervee, J. Cavenagh, S. Agrawal, T. Lister, J. Gribben & D. Bonnet (2008)

Anti-CD38 antibody mediated clearance of human repopulating cells masks the heterogeneity of leukaemia initiating cells.

Blood. 112. 568-575.

S.Lonial, P.Richardson, J. San Miguel, P. Sonneveld, M. Schuster, J. Blade, J.D.Cavenagh, S.Rajkumar, A.Jakubowiak, D-L. Esseltine, K.Anderson & J.L Harrousseau (2008)

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.

British Journal of Haematology. 143. 222-229.

J. San-Miguel, P. Richardson, P. Sonneveld, M.W. Schuster, D. Irwin, E.Stadtmauer, T.Facon, J-L. Harrousseau, D. Ben-Yahuda, S.Lonial, H.goldschmidt, D.Reece, J.Blade, M.Boccardo, J.D.Cavenagh, R.Neuwirth, A.Boral, D-L. Esseltine & K.C.Anderson (2008)

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

Leukemia. 22. 842-849.

B. Shaw, G. Mufti, S. Mackinnon, J.D.Cavenagh, R.Pearce, K. Towlson, J. Apperley, R.Chakraverty, C. Craddock, M. Kazmi, T. Littlewood, D.Milligan, A. Pagliuca, K. Thomson, D.Marks & N. Russell (2008)

Outcome of second allogeneic transplants using reduced intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.

Bone Marrow Transplantation. 42. 783-789.

M.Scully, H.Yarranton, R.Leisner, J.D.Cavenagh, B.Hunt, S.Benjamin, D.Bevan, I.Mackie & S.Machin (2008)

Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features.

British Journal of Haematology. 142. 819-826.

G.Morgan, F.E.Davies, J.D.Cavenagh & G.Jackson; on behalf of the United Kingdom Myeloma Forum (UKMF) and the Haematology Oncology Task Force of the British committee for Standards in Haematology (2008)

Position statement on the use of bortezomib in multiple myeloma.

International Journal of Laboratory Hematology. 30. 1-10.

J. Stevens, D. Syndercombe-Court, H.Oakervee, D.McCloskey, M.Jenner, J.Gribben & J.D.Cavenagh (2007)

Development of original donor cell leukaemia after successful engraftment from a second donor.

Blood. 110. 4621-4621.

P.G. Richardson, P.Sonneveld, M.Schuster, D.Irwin, E.Stadtmauer, T.Facon, J.L. Harousseau, D.Ben-Yahuda, S.Lonial, H.Goldschmidt, D.Reece, J. San Miguel, J.Blade, M.Boccadoro, J.Cavenagh, M.Alsina, S. Rajkumar, M.Lacy, A.Jakubowiak, W.Dalton, A.Boral, D.Esseltine, D.Schenkein & K. Anderson (2007)

Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Blood. 110. 3557-3560.

K.Summers, J.Stevens, I.Kakkas, M.Smith, L.L.Smith, F.MacDougall, J.D.Cavenagh, D.Bonnet, B.D.Young, T.A.Lister & J.Fitzgibbon (2007)

Wilm's Tumour1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML.

Leukemia. 21. 550-551.

Z.Lim, S.Killick, U.Germing, J.D.Cavenagh, D.Bowen, D.Culligan, A.Bacigalupo, J.Marsh & G.J.Mufti (2007)

Low IPSS score and bone marrow hypocellularity in MDS patients predict haematological responses to anti-thymocyte globulin.

Leukemia. 21. 1436-1441.

P.G.Richardson, P.Sonneveld, M.Schuster, D.Irwin, E. Stadtmauer, T.Facon, J.L.Harrousseau, D.Ben-Yehuda, S.Lonial, J. San Miguel, J.D.Cavenagh & K.C.Anderson (2007)

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

British Journal of Haematology. 137. 429-435.

H. Oakervee, R.Popat & J.D.Cavenagh (2007)

Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment.

Leukemia & Lymphoma. 48. 1910-1921.

M.Scully, H.Cohen, J.D.Cavenagh, S.Benjamin, R.Starke, S.Killick, I.Mackie & S.J.Machin (2007)

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

British Journal of Haematology. 136. 451-461.

N.Thorogood, S.Atwal, W.Mills, M.Jenner, D.A.Lewis, J.D.Cavenagh & S.G.Agrawal (2007)

The risk of antimalarials in patients with renal failure.

Postgraduate Medical Journal. 83. e8.

B.Sirohi, R.Powles, J.D.Cavenagh, H.Oakervee, P.Dyer, T.Rintala, S.Kulkarni, C.Rudin, C.Horton, J.Treleaven & G.Morgan (2007)

Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy.

Hematology. 12. 113-115.

B.J.Hunt, S.Tueger, J.Pattison, J.D.Cavenagh & D. D'Cruz (2007)

Microangiopathic haemolytic anaemia secondary to lupus nephritis-an important differential diagnosis of thrombotic thrombocytopenic purpura.

Lupus. 16. 358-362.

L.Y.Zhang, M.L.Smith, B.Schulteis, J.Fitzgibbon, T.A.Lister, J.V.Melo, N.C.P.Cross & J.D.Cavenagh (2006)

A novel K509I mutation of KIT identified in familial mastocytosis- in vitro and in vivo responsiveness to imatinib therapy.

Leukemia Research. 30. 373-378.

J.K.Davies, D.C.Taussig, H.Oakervee, A.J.Davies, S.G.Agrawal, J.G.Gribben, T.A.Lister & J.D.Cavenagh (2006)

Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukaemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host-disease.

Journal of Clinical Oncology. 24. e23-25.

D.P.J. Finnegan, P. Kettle, M.Drake, C.Matthews, H.D. Alexander, R.Popat, J.D.Cavenagh, W.Wachsman & T.C.M. Morris (2006)

Bortezomib is effective in primary plasma cell leukaemia.

Leukemia and Lymphoma. 47. 1670-1673.

S.B.Killick, J.D.Cavenagh, J.K.Davies & J.C.Marsh (2006)

Low dose antithymocyte globulin for the treatment of older patients with aplastic anaemia.

Leukemia Research. 30. 1517-1520.

J.K.Davies & J.D.Cavenagh (2006)

The importance of consistent use of denominators across patient groups in assessing responses in clinical trials.

British Journal of Haematology. 132. 794-795.

J. San Miguel, J. Blade, M. Boccadoro, J.D. Cavenagh, A. Glasmacher, S. Jagganath, S. Lonial, R.Z. Orlowski, P. Sonneveld & H.Ludwig (2006)
A practical update on the use of bortezomib in the management of multiple myeloma.

The Oncologist. 11. 51-61.

J.Quint, W.Mills, D.Lewis, J.D.Cavenagh & S.G.Agrawal (2006)
A complication of steroid therapy in acute leukaemia-a case report.
Hematology. 11. 97-99.

H.E.Oakervee, R.Popat, N.Curry, P.Smith, T.C.Morris, M.Drake, S.Agrawal, J.Stec, D.Schenkein, D-L Esseltine & J.D.Cavenagh (2005)
PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.
British Journal of Haematology. 129. 755-762.

P.G.Richardson, P.Sonneveld, M.W.Schuster, D.Irwin, E.A.Stadtmauer, T.Facon, J-L. Harrousseau, D. Ben-Yehuda, S.Lonial, H. Goldschmidt, D.Reece, J.F. San-Miguel, J.Blade, M.Boccadoro, J.D.Cavenagh, W.S.Dalton, A.L.Boral, D.L.Esseltine, J.B.Porter, D.Schenkein & K.C.Anderson (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
New England Journal of Medicine . 352. 2487-2498.

C.Crawley, M. Lalancette, R.Szydlo, M.Gilleece, K.Peggs, S.Mackinnon, G.Juliusson, L.Ahlberg, A.Nagler, A.Shimoni, A.Sureda, J-M. Boiron, H.Einsele, R.Chopra, A.Carella, J.D.Cavenagh, A.Gratwohl, F.Garban, A.Zander, B.Bjorkstrand, D.Niederwieser, G.Gahrton & J.F.Apperley (2005)
Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic markers from the chronic leukaemia working party of the the EBMT.
Blood. 105. 4532-4539.

M.L.Smith, R.Arch, L-L. Smith, N.Bainton, M.Neat, C.Taylor, D.Bonnet, J.D.Cavenagh, T.A.Lister & J. Fitzgibbon (2005)
Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.
British Journal of Haematology. 128. 318-323.

H.M.Hunter, K.Peggs, R.Powles, A.Rahemtulla, P.Mahendra, J.Cavenagh, T.Littlewood, M.Potter, A.Hunter, A.Pagliuca, C.D.Williams, G.Cook, K.Towlson, D.I.Marks & N.H.Russell (2005)
Analysis of outcome following allogeneic stem cell transplantation for myeloma using myeloablative conditioning-evidence for a superior outcome using melphalan combined with total body irradiation.
British Journal of Haematology. 128. 496-502.

A.C.Gordon, H.E.Oakervee, B.Kaya, J.M.Thomas, M.J.Barnett, A.Rohatiner, T.A.Lister, J.D.Cavenagh & C.J.Hinds (2005)

The incidence and outcome of critical illness amongst hospitalised patients with haematological malignancies: a prospective observational study of ward and intensive care unit based care.

Anaesthesia. 60. 340-347.

M.Cummins, K.Cwynarski, S.Marktel, F.Dazzi, J.D.Cavenagh, R.E.Clark, T.L.Holyoake, D.Milligan, A.Parker, N.H.Russell & D.I.Marks (2005)

Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the clinical trials committee of the British Society of Blood & Marrow Transplantation (BSBMT).

Bone Marrow Transplantation. 36. 1065-1069.

D.Bowen, L.MacIlwaine, J.D.Cavenagh, S.Killick, D.Culligan, E.Thomson & G.Mufti (2005)

Thalidomide therapy for low-risk myelodysplasia.

Leukemia Research. 29. 235-236.

M. Boccadoro, G. Morgan & J.D.Cavenagh (2005)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.

Cancer Cell International. 5. 18 (01 June 2005 on-line).

R.Popat, H.E.Oakervee & J.D.Cavenagh (2005)

Bortezomib combination therapy for multiple myeloma.

British Journal of Cancer Management. 2. 17-19.

R.Popat, H.E.Oakervee & J.D.Cavenagh (2005)

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for untreated patients with multiple myeloma: a case study and synopsis.

The American Journal of Oncology Review. 4. 750-759.

B.Kaya, C.E.Davies, H.E.Oakervee, N.C.Silver, J.Gawler & J.D.Cavenagh (2005)

Guillain Barre syndrome precipitated by the use of anti-lymphocyte globulin in the treatment of severe aplastic anaemia.

Journal of Clinical Pathology. 58. 994-995.

M. Battacharyya, H.Oakervee, C.Dalley, M.Glynn & J.D.Cavenagh (2005)

Hepatitis-associated aplastic anaemia treated successfully with antilymphocyte globulin.

Clinical and Laboratory Haematology. 5. 331-333.

A.N.Bennett, S.R.Sangle, W.Jan, M.Jenner, J.D.Cavenagh, G.Hughes & D.P.D'Cruz (2005)

Hepatomegaly as a rare presentation of Churg-Strauss syndrome.

Rheumatology. 58. 994-995.

M.L.Smith, J.D.Cavenagh, T.A.Lister & J.Fitzgibbon (2004)

Mutation of *CEBPA* in familial acute myeloid leukaemia.
New England Journal of Medicine . 351. 2403-2407.

S.Leaver, P.Amlot, R.Thuraisingham, A.Norton, C.Aitken & J.D.Cavenagh (2004)
Subacute immune responses to primary EBV infection leading to post-transplant lymphoproliferative disease in a renal transplant patient.
Clinical and Laboratory Haematology. 26. 351-3.

A.Pellagatti, N. Esoof, F. Watkins, C.F. Langford, D. Vetrie, L.J.Campbell, C.Fidler, J.D.Cavenagh, H.Eagleton, P.Gordon, B. Woodcock, M. Kwan, J.S.Wainscoat & J. Boulwood (2004)
Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology.
British Journal of Haematology. 125. 576-583.

J. Bird, J.D. Cavenagh, P. Hawkins, H. Lachmann, A. Mehta & D. Samson (2004)
Guidelines on the diagnosis and management of AL amyloidosis.
British Journal of Haematology. 125. 681-700.

S.Shah, J.D.Cavenagh, M.Sheaff & R.C.Thuraisingham (2004)
Remission of collapsing focal segmental glomerulosclerosis following chemotherapy for myeloma.
American Journal of Kidney Diseases. 4. 1534-1538.

R.Rajakariar, M. Bhattacharyya, A.Norton, M. Sheaff, J.D.Cavenagh, M. Raftery & M.Yaqoob (2004)
Post transplant T-cell lymphoma: A case series of four patients from a single unit and review of the literature.
American Journal of Transplantation. 4: 1534-1538.

B.E.Shaw, K.Peggs, J.M. Bird, J.D.Cavenagh, A.Hunter, A.J.Madrigal, N.H.Russell, B. Sirohi, K.Towlson, C.D.Williams & D.I.Marks (2003).
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma.
British Journal of Haematology. 123. 886-895.

D.C.Taussig, A.J.Davies, J.D.Cavenagh, H.Oakervee, D. Syndercombe-Court, S.Kelsey, J.A.L.Amess, A.Z.Rohatiner, T.A.Lister & M.J.Barnett (2003)
Durable remissions of myelodysplastic syndrome and acute myeloid leukaemia after reduced-intensity allografting.
Journal of Clinical Oncology. 21: 3060-3065.

J.D.Cavenagh & H.Oakervee (2003)
Thalidomide in multiple myeloma: current status and future prospects.
British Journal of Haematology. 120. 18-27.

S.A.Schey, J.D.Cavenagh, R.Johnson, J.A.Child, H.Oakervee & R.W.Jones (2003)

An UK Myeloma Forum Phase II study of thalidomide; long-term follow-up and recommendations for treatment.
Leukemia Research. 27. 909-914.

S.B.Killick, G.Mufti, J.D.Cavenagh, A.Mijovic, J.Peacock, E.C.Gordon-Smith, D.T.Bowen & J.C.W.Marsh (2003)
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low risk' myelodysplasia.
British Journal of Haematology. 120. 679-684.

J.Davies, P.Telfer, J.D.Cavenagh, N.Foot & M.Neat (2003)
Autoimmune cytopenias in the 22q11.2 deletion syndrome.
Clin Lab Haematol. 25. 195-7.

D.I.Marks, R.Lush, J.D.Cavenagh, D.W.Milligan, S.Schey, A.Parker, F.J.Clark, L.Hunt, J.Yin, S.Fuller, E.Vandenberghe, J.Marsh, T.Littlewood, G.M.Smith, D.Culligan, A.Hunter, R.Chopra, A.Davies, K.Towlson & C.D.Williams (2002)
The toxicity and efficacy of donor lymphocyte infusions given after reduced intensity conditioning allogeneic stem cell transplantation.
Blood . 100. 3108-3114.

H.J.Longhurst, D.Taussig, T. Haque, D.S.Court, J.Cavenagh, J.D.Edgar & M.R.Helbert (2002)
Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome.
British Journal of Haematology. 116. 497-499.

H.J.Longhurst, C.O'Grady, G.Evans, C. De Lord, A.Hughes, J.Cavenagh & M.R.Helbert (2002)
Anti-D immunoglobulin treatment for thrombocytopenia associated with primary antibody deficiency.
Journal of Clinical Pathology. 55. 64-66.

E.Matutes, G.P.Taylor, J.D.Cavenagh, A.Pagliuca, D.Bareford, A.Domingo, M.Hamblin, S.Kelsey, N.Mir, J.T.Reilly & D.Catovsky (2001)
Interferon- α and zidovudine therapy in adult T-cell leukaemia lymphoma (ATLL). Response and outcome in 15 patients.
British Journal of Haematology. 113. 779-785.

N.C.McBride, J.D.Cavenagh, M.C.Ward, I.Grant, S.Schey, A.Gray, A.Hughes, M.J.Mills, P.Cervi, A.C.Newland & S.M.Kelsey (2001)
Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin's lymphoma.
Leukemia and Lymphoma. 42. 89-98.

L.Silberstein, A.Davies, S.Kelsey, J.Foran, C.Murrell, D.C'Cruz, S.Vinnicombe, A.Norton & J.D.Cavenagh (2001)
Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft versus host disease after non-

myeloablative peripheral blood stem cell transplantation and subsequent donor lymphocyte infusion.

Bone Marrow Transplantation. 27. 231-233.

M.Helbert, S.Bodger, J.D.Cavenagh, D.D'Cruz, Thomas JM & P.MacCallum (2001)

Optimising tests for antiphospholipid antibodies.

Journal of Clinical Pathology. 54. 693-698.

C.D.Dalley, T.A.Lister, J.D.Cavenagh & A.Z.Rohatiner (2001)

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia.

British Journal of Cancer. 84. 147.

A.C.Newland, J.D.Cavenagh, I.Burton, A.Copplestone, G.Dolan, J.Houghton & T.Reilly (2001)

Vigam-S, a solvent/detergent treated intravenous immunoglobulin, in idiopathic thrombocytopenic purpura.

Transfusion Medicine. 11. 37-44.

P.R.Smith, J.D.Cavenagh, T.Milne, D.Howe, S.J.Wilkes, P.Sinnott, G.E.Forster & M.Helbert (2000)

Benign monoclonal expansion of CD8+ lymphocytes in HIV infection.

Journal of Clinical Pathology. 53. 177-181.

N.C.McBride, J.D.Cavenagh, A.C.Newland, D.M.Lillington, C.Murrell & S.M.Kelsey (2000)

Autologous transplantation with Philadelphia-negative progenitor cells for patients with chronic myeloid leukaemia (CML) failing to attain a cytogenetic response to alpha interferon

Bone Marrow Transplantation. 26. 1165-1172.

I.N.M.Micaleff, J.Apostilidis, A.Z.S.Rohatiner, C.Wiggins, C.Crawley, J.Foran, M.Leonhardt, M.Bradburn, E.Okukenu, A.Salam, J.Matthews, J.D.Cavenagh, R.K.Gupta & T.A.Lister (2000)

An analysis of factors which predict failure to mobilise peripheral progenitor cells (PBPC) with G-CSF alone in patients with non-Hodgkin's lymphoma.

The Hematology Journal. 1. 367-373.

Faivre L, Guardiola P, Lewis C et al for the European Fanconi Anemia Research Group (2000)

Association of complementation group and mutation type with clinical outcome in Fanconi anemia.

Blood. 96. 4064-4070.

M.J.Jenner, I.M.M. Micaleff, A.Z.Rohatiner, S.M.Kelsey, A.C.Newland & J.D.Cavenagh (2000)

Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.

Medical Oncology. 17. 333-336.

N.C.McBride, M.C.Ward, M.J.Mills, A.G.Eden, A.Hughes, J.D.Cavenagh, A.Lamont, A.C.Newland & S.M.Kelsey (1999)

EPIC as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to BEAM high dose chemotherapy and peripheral blood progenitor cell transplantation.

Leukemia and Lymphoma. 35. 339-345.

M.G.Macey, D.A.McArthy, T.Milne, J.D.Cavenagh & A.C.Newland (1999)

Comparative study of five commercial reagents for preparing normal and leukaemic lymphocytes for immunophenotyping by flow cytometry.

Cytometry (Comm.Clin.Cytometry). 38.153-160.

P.Smith, M.Helbert, M.Raftery, F.Forster & J.D.Cavenagh (1999)

Paraproteins and monoclonal expansion of CD3+CD8+CD56-CD57+ T lymphocytes in a patient with HIV infection.

British Journal of Haematology.105. 85-88.

M.Wijker, N.V.Morgan, S.Heterich, C.G.M.van Berkel, A.J.Tipping, H.J.Gross, J.J.P.Gille, G.Pals, M.Savino, C.Altay, S.Mohan, I.Dokal, J.D.Cavenagh, J.Marsh, M. van Weel, J.J.Ortega, D.Schuler, E.Samochatova, M.Karwacki, A.N.Bekassy, M.Abecasis, W.Ebell, M.L.Kwee, T. de Ravel, R.A.Gibson, E.Gluckman, F.Arwert, H.Joenje, A.Savoia, H.Hoehn, J.C.Pronk & C.G.Mathew (1999)

Heterogeneous spectrum of mutations in the Fanconi anaemia group A gene.

European Journal of Human Genetics. 7. 52-59.

M.G.Macey, L.Hou, T.Milne, V.Parameswaren, D.Howe, J.D.Cavenagh, G.L.Howells & A.C.Newland (1998)

A CD4+ proliferation of large granular lymphocytes expresses the protease activated receptor-1

British Journal of Haematology. 101. 78-81.

M.R.Cahill, M.G.Macey, J.D.Cavenagh & A.C.Newland (1998)

Protein A immunoadsorption in chronic ITP reverses increased platelet activation but fails to achieve sustained clinical benefit.

British Journal of Haematology. 100. 358-365.

J.D.Cavenagh, T.M.Milne, M.G.Macey & A.C Newland (1997)

Thymic function in adults: evidence derived from immune recovery patterns following myeloablative chemotherapy and stem cell infusion.

British Journal of Haematology. 97. 673-677.

D.S.Richardson, S.M.Kelsey, S.A.Johnson, M.Tighe, J.D.Cavenagh & A.C.Newland (1997)

Liposomal daunorubicin in the treatment of relapsed and refractory lymphoma.

Investigational New Drugs. 15. 247-253.

D.T.Nguyen, L.W.Diamond, J.D.Cavenagh, R.Parameswaran & J.A.Amess (1997)

Haematologic validation of a computer-based bone marrow reporting system.
Journal of Clinical Pathology. 50. 375-378.

D.T.Nguyen, L.W. Diamond, J.D.Cavenagh, E.Morris, R.Parameswaran & J.A.Amess (1997)
Increased efficiency of bone marrow reporting with hematology knowledge-based systems.
Laboratory Haematology. 3. 10-18.

J.D.Cavenagh, D.S.Richardson, R.A.Gibson, C.G.Mathew & A.C.Newland (1996).
Fanconi's anaemia presenting as acute myeloid leukaemia in adulthood.
British Journal of Haematology. 94. 126-129

D.Tsetsis, J.Bhattacharya, J.D.Cavenagh & C.Thakkar (1996)
CT and MRI demonstration of hypothalamic and infundibular relapse in childhood acute lymphoblastic hypothalamic and infundibular leukaemia.
British Journal of Radiology. 69. 269-271.

J.D.Cavenagh, D.S.Richardson, M.R.Cahill, T.Bernard, S.M.Kelsey & A.C.Newland (1995).
Treatment of acute myeloid leukaemia in pregnancy.
Lancet. 346. 441-442.

M.Karakantza, J.D.Cavenagh, E.C.Gordon-Smith & F.M.Gibson (1995)
Adhesion molecule expression on CD34+ progenitor cells from normal and aplastic anaemia bone marrow.
British Journal of Haematology. 91. 800-804.

A.J.Rae, J.D.Cavenagh & B.T.Goh (1995)
Haemoglobin SC disease presenting as a case of priapism to a GUM clinic.
International Journal of STD & AIDS. 6. 361-2.

J.D.Cavenagh, A.Joseph, S.Dilly & D.H.Bevan (1994).
Splenic sepsis in sickle cell disease.
British Journal of Haematology. 86. 187-190.

M.Karakantza, F.M.Gibson, J.D.Cavenagh, S.E.Ball, M.Y.Gordon & E.C.Gordon-Smith (1994).
SLe^x expression on normal CD34 positive bone marrow haemopoietic cells.
British Journal of Haematology. 86. 883-887.

J.D.Cavenagh, E.C.Gordon-Smith, F.M.Gibson & M.Y.Gordon (1993).
Acute myeloid leukaemia blast cells bind to human endothelium *in vitro* utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1) .
British Journal of Haematology. 85. 285-292.

A.Zuible, J.Treleaven, R.L.Powles, H.Aboud, C.Tiley, M.Kenny & J.D.Cavenagh (1991).

Acute myeloid leukaemia following matched allogeneic bone marrow transplantation for T-cell lymphoblastic lymphoma.
Leukaemia and Lymphoma. 5. 431-433.

D.Talbot, R.L. Powles, J. Sloane, J. Treleaven, H.Aboud, M.Rowley, J.D.Cavenagh, S.Milliken, M.Hewetson & J.Norton (1990).
Cyclosporin induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.
Bone Marrow Transplantation. 6. 17-20.

P.Parikh, R.L.Powles, J.Treleaven, G.Helenglass, M.Gore, M.Rose, D.Talbot, S.Milan, C.Smith, R.Pinkerton, H.Aboud, J.D.Cavenagh, M.Rowley, T.McElwain & M.Hewetson (1990).
High-dose cytosine arabinoside plus etoposide as initial treatment for acute myeloid leukaemia: a single centre study.
British Journal of Cancer. 62. 830-833.

The Intersalt Cooperative Research Group (1988)
Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion.
British Medical Journal. 297. 319-328.

Peer-reviewed papers where listed as investigator.

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, (2017)
Daratumumab, Lenalidomide and Dexamethasone for Multiple Myeloma.
New England Journal of Medicine. 375.1319-1331.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators (2017)
Long-term outcomes of imatinib treatment for chronic myeloid leukemia.
New England journal of Medicine. 376. 917-927.

G.Morgan, F.Davies, W.Gregory, A.Szubert, S.Bell, M.Drayson, R.Owen, A.Ashcroft, G.Jackson & J.Child (2012)
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Blood. 119. 5374-83.

G.Morgan, W.Gregory, F.Davies, S.Bell, A.Szubert, J.Brown, N.Coy, N.Russell, C.Rudin, H.Roddie, M.Drayson, R.Owen, F.Ross, G.Jackson & J.Child (2012)

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.
Blood. 119. 7-15.

G.Morgan, F.Davies, W.Gregory, S.Bell, A.Szubert, N.Coy, G.Cook, S.Feyler, P.Johnson, C.Rudin, M.Drayson, R.Owen, N.Russell, G.Jackson & J.Child (2012)
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomised trial patients.
Haematologica. 97. 442-450.

P.Fenaux, G.Mufti, E.Hellstrom-Lindberg, V.Santini, C.Finelli, A.Giagounidis, R.Schoch, N.Gattermann, G.Sanz, A.List, S.Gore, J.Seymour, J.Bennett, J.Byrd, J.Backstrom, L.Zimmerman, D.McKenzie, C.Beach & L.Silverman; International Vidaza High-Risk MDS Survival Study Group (2009)
Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study.
Lancet Oncology. 10. 223-232.

Invited review articles

K.Liapis & J.D.Cavenagh
Toward a better management of older patients with acute myeloid leukemia (2015)
Future Oncology. 11. 715-718

V.Foggo & J.D.Cavenagh
Malignant causes of fever of unknown origin (2015)
Clinical Medicine. 15. 292-294.

S.Hassan & J.D.Cavenagh
Multiple Myeloma (2015)
Trends in Urology and Men's Health (Jan-Feb, pages 31-34)

S.Lonial & J.D.Cavenagh (2009)
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
British Journal of Haematology (in press)

M.Dicato, M. Boccadoro, J.D.Cavenagh, J-L. Harrousseau, H.Ludwig, J. San Miguel, P.Sonneveld for the Multiple Myeloma Experts Debate Group (2006).
Management of multiple myeloma with bortezomib: experts review the data and debate the issue.
Oncology. 70. 474-482.

J.D.Cavenagh (2006)

White Blood Cells.
Surgery (Oxford),. 25. 61-64.

J.D.Cavenagh (2006)
Additional dexamethasone improves the response rate among patients with multiple myeloma treated with single agent bortezomib.
Haematologica, 91. 869.

R.Popat, S.Joel, H.Oakervee & J.D.Cavenagh (2006)
Bortezomib for multiple myeloma.
Expert Opin Pharmacother. 7. 1337-1446.

J.D.Cavenagh (2004)
The White Cell.
MEDICINE. 32:5:4-6.

H.Oakervee & J.D.Cavenagh (2002)
The role of thalidomide in the treatment of myeloma.
Current Medical Literature-Leukaemia and Lymphoma. 12. 85-91.

H.Oakervee & J.D.Cavenagh (2003)
Thalidomide.
Cancer Topics. 12. 5-8.

M.Helbert & J.D.Cavenagh (1998)
Immune reconstitution after bone marrow/stem cell transplantation.
Current Medical Literature-Leukaemia and Lymphoma. 6. 103-107.

J.D.Cavenagh, M.R.Cahill & S.M.Kelsey (1998)
Adhesion molecules in clinical medicine.
Critical Reviews in Clinical Laboratory Sciences. 34. 415-459.

V.Vijay, J.D.Cavenagh & P.Yate (1998)
The anaesthetist's role in acute sickle cell crisis.
British Journal of Anaesthesia. 80. 820-828.

J.D.Cavenagh & B.T.Colvin (1996)
Guidelines for the management of thrombophilia.
Postgraduate Medical Journal. 72. 87-94.

J.D.Cavenagh, E.C.Gordon-Smith & M.Y.Gordon (1994)
The binding of acute myeloid leukemia blast cells to human endothelium.
Leukemia and Lymphoma. 16. 19-29.

Book Chapters

S.Hassan & J.D.Cavenagh
Multiple Myeloma.

In: ABC of Clinical Haematology, Ed. D.Provan (4th Edition) (2018)

J.D.Cavenagh, N.Raje, E.Terpos & P.Croucher
Bone Disease.

In: Multiple Myeloma: State of the Art, Ed. P.G.Richardson & K.C.Anderson, Remedica (2011).

J.Malpas & J.D.Cavenagh

Clinical presentation, laboratory diagnosis and indications for treatment

In: Myeloma: Biology and Management. Ed. J.Malpas, D.E.Bergsagel, R.A.Kyle and K.Anderson (3rd Edition) (2004).

J.Malpas & J.D.Cavenagh

Plasmacytoma

In: Myeloma: Biology and Management. Ed. J.Malpas, D.E.Bergsagel, R.A.Kyle and K.Anderson (3rd Edition) (2004).

J.D.Cavenagh & P.Croucher

Bone Disease.

In: Multiple Myeloma, Ed. P.G.Richardson & K.C.Anderson, Remedica (2004).

J.D.Cavenagh & T.A.Lister

Chronic lymphocytic leukaemia: diagnosis and management.

In: Current Clinical Oncology: Chronic Leukemias and Lymphomas, Ed. G.J.Schiller, Humana Press Inc (2002).

J.D.Cavenagh

Anaemia and coagulation disorders.

In: Hutchison's Clinical Methods (21st Edition), Ed. M.Swash, W.B.Saunders (2002).

J.D.Cavenagh, M.G.Macey & T.M.Milne

Immunophenotypic analysis of leukocytes in disease.

In: Cytometric analysis of cell phenotype and function, Eds. M.G.Macey & D.A.McCarthy, Cambridge University Press (2001).

J.D.Cavenagh & B.T.Colvin

Haemostasis and its assessment.

In: Textbook of Intensive Care, Eds. D.Goldhill & S.Withington, Chapman and Hall (1997).